2023年P(guān)FO封堵后房顫PPT

AmJCardiol2002;89:39-43Among455patient術(shù)前有無心律失常術(shù)前有無心律失常Arrhythmia&ElectrophysiologyReview EfficacyCompletePFOcl27246046000063PFOclosureModlealtherapy3333WelghtM-H,Random.95%C2.1.3HelexorCardioformSepTentforoveratefectZ=2.69(P=0.022HelarogenetyTau=047.Ch=8.15.df=4P=009)P=5TentforoveratefectZ-3.74(o06(log-ranktest;p<0.001)[ColoAmplatzerPFOandGORE(HelexandCARDIOAmplatzerPFOandGORE(HelexandCARDIO√√Amplatzerdevice:3.93%(30/763)vs.p=0.006>765項研究中，篩查出45項納入分析>平均年齡37-67歲結(jié)論：現(xiàn)有研究很難衡量PFO封堵與AF發(fā)病率之間的關(guān)聯(lián)and0.014person-yearsforthewithin6population(n=35)最常見于前2周。1例9個月發(fā)生，與PFOO無關(guān)37%??監(jiān)測方法差異>>2016~2020,761個PFOO回顧分析>622例未植入循環(huán)記錄儀(ILR),64例植入，>PIAF發(fā)生率37%(13/35),12例PFOO前4周，CatheterCardiovascInterv.2022;100:219-224.>2018.6~2020.10,所有PFOO進(jìn)行心電監(jiān)測per10-yearincrease;95%Cl:1.18-2.36),devicemalesex(adjustedOR:4.78;95Age,y52.2(43.3-59.5)47.4(37.2-64.8)57.0(50.4-65.8)49.3(4√術(shù)后持續(xù)心動過速：4.4%(10/225)√ELR發(fā)現(xiàn)：9.9%(13/132)√ILR發(fā)現(xiàn)：28.9%(24/83AfterAll,JACC:CardiovascularInterventions(2022),doi:/10.1016/jjcin.2022.08.022.1.年齡：3個RCT,年齡<60歲，這個研究25%年齡超過60歲/10.1016[CI]1.76-4.51;P<.001)anddia4.18;P<.001)werestatisticallysignificant,independen使用安大略15年醫(yī)療數(shù)據(jù)分析>1533例患者中，96例(6.26%)在>平均隨訪時間為8.2年>年齡大于6O歲和糖尿病是獨立房顫相對較低。糖尿病和年齡大于6O歲ChristianValdemarSkibstedUniversityHospitalA1001,PalleJuul-JeReceived9November2022;revised配組房顫的HR為51(95%CI:21～125),37AF,atrialfibrillationorflutter;Cl,confidenceinterval;PFO,patentforamenovale;PY,pey機(jī)制不清楚?發(fā)作時間/危害發(fā)作時間發(fā)作時間PFOclosureisassociatedwithanincreasedriskofnew-onsetAF.Subtotalr'-74.728%,Heterogenetybetweengroups:p-0LT-persistent.28%(9/703)&藥物0.86%(6/691)26%(10/441)&藥物0.28%(9/703)&藥物0.86%(6/691)26%(10/441)&藥物0.EwurtsTotulEwntsTotalMH.Random,95%CMHHodorogonoty.Tan2=00RCN=340.d=3(P=033).P=12%“serious“seriousAF”44%B“SeriousAFcases”AmplatzerRESPECTAmplatzerRESPECTaHetorogenety.Tau=0.00;C=0.29,Helerogeneity:.Tau'=0.00,Che=0.18.d=1(P=067TestforoveralleffecREDUCEREDUCETestforoveraleflect:ZeffectZ=3.12(P=0.002)forTestforoveralleflectsubgroupdiferences:ChF=265.df=1(P=0.subgroupdiferences:ChF=265.df=1(P=0.higherthanMT,evenwhenanalyConclusionsNMAsupptheriskofAFbyover2/4times(seriousorunseriousAF).ConsiderinAMPAMP36/901=4%